Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pholcodine→

Pholcodine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
509-67-1
Molecular formula
C23H30N2O4
Molecular weight
398.5 g/mol
Drug class
Opioid antitussivecentrally acting cough-reflex suppressant
Mechanism of action
Acts centrally on the medullary cough centre, reducing the neural signals that trigger cough. It has opioid-related pharmacology but is used primarily as an antitussive rather than as an analgesic.
Indications / reported uses
  • Historically used for symptomatic treatment of non-productive (dry) cough in adults and children, including in combination cold-and-flu products.
  • Pholcodine-containing medicines were withdrawn from the EU market in 2023 because use in the preceding 12 months was associated with an increased risk of peri-anaesthetic anaphylaxis to neuromuscular blocking agents. Current availability and restrictions vary by jurisdiction.

Sources: https://www.ema.europa.eu/en/medicines/human/referrals/pholcodine-containing-medicinal-products · https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-pholcodine-medicines-eu-market · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Opioid antitussive; centrally acting cough-reflex suppressant

Mechanism of action

Acts centrally on the medullary cough centre, reducing the neural signals that trigger cough. It has opioid-related pharmacology but is used primarily as an antitussive rather than as an analgesic.

General use cases

  • Historically used for symptomatic treatment of non-productive (dry) cough in adults and children, including in combination cold-and-flu products.
  • Pholcodine-containing medicines were withdrawn from the EU market in 2023 because use in the preceding 12 months was associated with an increased risk of peri-anaesthetic anaphylaxis to neuromuscular blocking agents. Current availability and restrictions vary by jurisdiction.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Pholcodine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pholcodine Permitted Daily Exposure (PDE) report (the Pholcodine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pholcodine Occupational Exposure Limit (OEL) report (the Pholcodine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.